Acurable Revenue and Competitors

London, London

Location

#4565

Growjo Ranking

Medical

Industry

Estimated Revenue & Valuation

  • Acurable's total funding is $14M.

Employee Data

  • Acurable has 33 Employees.(i)
  • Acurable grew their employee count by 38% last year.

Acurable's People

NameTitleEmail/Phone
1
Head Engineering and Co-FounderReveal Email/Phone
2
co-CEO & CSOReveal Email/Phone
3
co-CEO & COOReveal Email/Phone
4
Head PlatformReveal Email/Phone
5
Head PlatformReveal Email/Phone
6
Commercial Director EuropeReveal Email/Phone
7
HR and People Ops ManagerReveal Email/Phone
8
Clinical Development ManagerReveal Email/Phone
9
Research ScientistReveal Email/Phone
10
Product Development CoordinatorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
N/A23-36%N/AN/A
#2
N/A129%N/AN/A
#3
N/A90%N/AN/A
#4
N/A3338%$13.6MN/A
#5
N/A3521%$1.72MN/A
#6
N/A2414%$4.31MN/A
Add Company

What Is Acurable?

Acurable is a fast-growing, venture backed MedTech start-up with offices in London and Seville. We create accurate and user-friendly wearable medical devices intended to be used by patients at home. Our award-winning, patented technology enables for the first time the automated diagnosis and management of respiratory conditions. It is the product of more than 10 years’ research at Imperial College London by Acurable’s founder, Professor Esther Rodriguez Villegas, and has been recognised as a breakthrough in respiratory medicine, winning some of the most respected awards in the industry, among them an XPrize and several Innovate UK grants. It has also featured in national and international media, including earlier this year in the BBC Horizon documentary How to Sleep Well with Michael Mosley. In 2020 our first product, AcuPebble SA100, became the first medical device in the world to obtain the CE mark for the automated diagnosis of obstructive sleep apnoea at home, and a few months later the product gained FDA clearance for home sleep apnoea testing in the US. AcuPebble SA100 is now in use within healthcare organisations across the UK and Europe, and will be launching in the USA in the coming months. At the same time we continue our research to develop new products that will fundamentally improve the lives of millions of people suffering from serious chronic conditions such as COPD, Asthma and Epilepsy.

keywords:N/A

$14M

Total Funding

33

Number of Employees

N/A

Revenue (est)

38%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.8M33-33%N/A
#2
$3.8M330%$6M
#3
$7.1M33-8%N/A
#4
$3.2M33-3%N/A
#5
$3.8M336%N/A